Clinical Trial Update: Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases [Phase 1]

View source ↗

Summary

This Phase 1 trial update describes dose optimization and expansion of the investigational compound DFV890 in adult patients with myeloid diseases, sponsored by…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloid Diseases

Drugs mentioned

• DFV890

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myeloid Diseases | Phase 1 | Status: ACTIVE_NOT_RECRUITING